Project Grant R42DK138693
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1.3M
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Eugene, OR 97403, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $356,328 to Celdara Medical, LLC on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel allogeneic cell therapy for difficult-to-treat inflammatory bowel disease. Celdara will develop cell-based therapeutic candidates targeting the dysregulated immune response in IBD patients who fail multiple lines of conventional therapy or experience...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of California, Davis $180,109 on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate restoration of microbiota signaling pathways using non-biotic substitutes—termed "faux-biotics"—to control opportunistic infections during chemotherapy-induced dysbiosis. The project addresses the loss of colonization resistance that occurs...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Medosome Biotec LLC $356,251 on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop genetically engineered probiotics capable of producing and delivering glucagon-like peptide-1 (GLP-1) for treatment of metabolic diseases including type 2 diabetes and obesity. The project addresses limitations of existing GLP-1 receptor agonist therapies—poor patient...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $698,501 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify gene-level interactions between host immunity and the intestinal microbiota that regulate inflammation in inflammatory bowel disease. The funded research combines microbiota analysis tools, host single-cell RNA sequencing, and machine learning methods to...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Immunyx Pharma USA Inc. $4,056,301 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop IMYX-3, a small-molecule RAB27A inhibitor for treatment of ulcerative colitis. The award funds development of a soluble RAB27A inhibitor targeting patients with moderate-to-severe ulcerative colitis refractory to existing biologic therapies. RAB27A, a monomeric...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham and Women's Hospital Inc. $193,776 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify cytokine biomarkers that predict response to IL-23 p19 inhibitor therapies for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The research will quantify cytokines related to IL-23 signaling in serum and inflamed...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Keylicon Biosciences Inc. $400,000 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel long-acting glucocerebrosidase therapy for Gaucher disease. Keylicon is developing a self-amplifying RNA platform that encodes both glucocerebrosidase and an RNA-dependent RNA polymerase on a single strand, enabling in situ production of the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Arizona $100,228 on December 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic biomedical research investigating the role of acid ceramidase in myeloid cells on intestinal inflammation. The research aims to elucidate how acid ceramidase—an enzyme highly expressed in inflammatory bowel disease and colitis-associated cancer—modulates...
- Federal Project Grant Award Summary Lactiga US Inc. received a $303,427 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2026. The award supports development of a proprietary therapeutic derived from human milk-based secretory IgA (sIgA) for oral delivery to treat Inflammatory Bowel Disease (IBD). The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Beckman Research Institute of The City of Hope $280,232 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research on gut-fat crosstalk in metabolic regulation. The award supports basic and translational research investigating intestinal mTOR signaling and its effects on white adipose tissue browning, glucose homeostasis, and energy metabolism....